Related Experiment Videos
New agents in ovarian cancer
Abstract:
A small number of women with metastatic ovarian cancer can now be cured with cytotoxic agents. The majority, however, succumb and die. To aid in the search for new and more effective agents the National Cancer Institute has developed a preclinical screening program using human tumor xenografts in nude mice in addition to the more traditional experimental animal tumors. A number of cancer centers and cooperative clinical groups have developed programs for human trials. The recent development of an ovarian cancer clonogenic assay may provide an additional in vitro method for identifying useful new drugs specifically directed against ovarian cancer.
Insights
New preclinical models and assays are being developed to find better treatments for metastatic ovarian cancer. These approaches aim to improve cure rates beyond current cytotoxic agents for this challenging disease.
Area of Science:
- Oncology
- Cancer Research
- Drug Discovery
Background:
- Metastatic ovarian cancer has a poor prognosis, with only a small subset of patients benefiting from current cytotoxic chemotherapy.
- The majority of patients with advanced ovarian cancer succumb to the disease, highlighting the urgent need for more effective treatments.
Purpose of the Study:
- To describe the development of novel preclinical models and in vitro assays for identifying new therapeutic agents against ovarian cancer.
- To support the National Cancer Institute's efforts in discovering more effective treatments for ovarian cancer.
Main Methods:
- Utilizing human tumor xenografts in nude mice as a preclinical screening model.
- Employing traditional experimental animal tumors for drug evaluation.
- Developing and implementing an ovarian cancer clonogenic assay for in vitro drug screening.
Main Results:
- The National Cancer Institute has established a preclinical screening program incorporating human tumor xenografts.
- Cancer centers and cooperative groups are actively conducting human trials for ovarian cancer.
- The ovarian cancer clonogenic assay shows promise as an in vitro method for drug identification.
Conclusions:
- Advancements in preclinical models and in vitro assays are crucial for discovering novel ovarian cancer therapies.
- These new methods complement existing approaches and aim to improve treatment outcomes for patients with metastatic ovarian cancer.